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Abstract
Objective—To evaluate QRISK2 and Framingham cardiovascular disease (CVD) risk scores in a 
tri-ethnic UK population.
Design—Cohort study.
Setting—West London.
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Participants—Randomly selected from primary care lists. Follow-up data were available for 
87% of traced participants, comprising 1866 white Europeans, 1377 South Asians, and 578 
African Caribbeans, aged 40–69 years at baseline (1998–1991).
Main outcome measures—First CVD events: myocardial infarction, coronary 
revascularisation, angina, transient ischaemic attack or stroke reported by participant, primary care 
or hospital records or death certificate.
Results—During follow-up, 387 CVD events occurred in men (14%) and 78 in women (8%). 
Both scores underestimated risk in European and South Asian women (ratio of predicted to 
observed risk: European women: QRISK2: 0.73, Framingham: 0.73; South Asian women: 
QRISK2: 0.52, Framingham: 0.43). In African Caribbeans, Framingham over-predicted in men 
and women and QRISK2 over-predicted in women. Framingham classified 28% of participants as 
high risk, predicting 54% of all such events. QRISK2 classified 19% as high risk, predicting 42% 
of all such events. Both scores performed poorly in identifying high risk African Caribbeans; 
QRISK2 and Framingham identified as high risk only 10% and 24% of those who experienced 
events.
Conclusions—Neither score performed consistently well in all ethnic groups. Further validation 
of QRISK2 in other multi-ethnic datasets, and better methods for identifying high risk African 
Caribbeans and South Asian women, are required.
Introduction
Risk prediction is a cornerstone of strategies for prevention of cardiovascular disease 
(CVD).1 2 The last 30 years have seen the derivation and modification of numerous risk 
calculators.3–10 People of South Asian origin experience greater risk than people of 
European origins, while in the UK, people of African Caribbean origin have lower risks of 
coronary heart disease (CHD), but higher risks of stroke.11 Earlier UK studies reported that 
the Framingham score (developed in a largely white US community) predicted no difference 
in risk between South Asians and white Europeans either with diabetes or in the general 
population in terms of CVD mortality12 and CHD and stroke risk.13 14 The Framingham 
score has been criticised for lack of socioeconomic adjustment, overestimating risk in low 
risk and affluent populations, while underestimating risk in less affluent populations.15–17
More recently, QRISK2, including adjustment for deprivation and ethnicity, has undergone 
internal and external validation using UK primary care datasets.4 18 However, the 
performance of QRISK2 in ethnic minorities was not reported separately.18 Earlier 
guidelines from the UK National Institute for Health and Care Excellence (NICE) 
recommended lower risk thresholds for South Asian men (but not women), by multiplying 
the Framingham risk scores by 1.4,3 19 although this approach remains untested. In 2010 
NICE recommended that the Framingham risk equation would no longer be recommended 
for CVD risk assessment, but that it could be considered together with other risk scores such 
as QRISK2. We evaluated the performance of Framingham3 19) and QRISK2 scores as 
predictors of CVD outcomes over 10 years of follow-up in European, South Asian, and 
African Caribbean men and women in a UK population based cohort.
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Methods
SABRE (Southall And Brent REvisited) is a tri-ethnic, community based cohort from 
Southall and Brent (London).20 Participants aged 40–69 years at baseline (1988–1991) were 
randomly selected from primary care physician lists (n=4063) and workplaces (n=795). 
Ethnicity was agreed with the interviewer based on self-report, parental origins, and 
appearance. All South Asians and African Caribbeans were migrants. South Asians 
originated from the Indian subcontinent (India 90.3%, Pakistan 9.4%). Most African 
Caribbeans (92.5%) originated from the Caribbean and the remainder from West Africa.
At baseline, participants underwent fasting and post-glucose challenge blood tests, blood 
pressure measurements, ECG, anthropometry, and completed a health and lifestyle 
questionnaire.20 Minnesota criteria21 identified major Q waves on ECG. Atrial fibrillation 
and left ventricular hypertrophy (LVH) were identified in a subset of ECGs from European 
and African Caribbean participants.20 Diabetes was determined using WHO criteria22 or 
doctor diagnosed diabetes. Seated resting blood pressure was taken as the average of two 
readings measured using a random zero sphygmomanometer (Hawksley, UK).
Deaths were reported by the Office for National Statistics. During 2008–2011, survivors 
were invited to join a follow-up. This included a health and lifestyle questionnaire and/or 
primary care medical record review and/or attendance at our clinic at St Mary’s Hospital, 
London. Hospital episode statistics (HES) were obtained.
At follow-up we obtained data on family history of CHD, defined as angina or heart attack 
diagnosed in a parent aged under 60 years. We assigned Townsend 2001 deprivation scores 
based on output areas.4
Identification of cardiovascular events during the first 10 years of follow-up
We mirrored end points for QRISK2 (first myocardial infarction, angina, CHD, stroke, 
transient ischaemic attack). We included coronary revascularisation procedures as these 
procedures incur a diagnosis of CHD on the general practice database.
For CHD, we identified the first event from any of the following sources:
A. Cause of death includes International Classification of Disease (ICD) 9 
codes 410-415 or ICD10 codes I200-I259.
B. Primary care record review.
C. Participant reported coronary revascularisation or acute myocardial 
infarction.
D. HES: diagnostic ICD9 codes 410-415 or ICD10: I200-I259 or the Office 
of Populations and Surveys ‘Classification of interventions and 
procedures’: K401-K469, K491-504, K751-759 or U541.
For stroke/transient ischaemic attack, we identified the first event from any of the following 
sources:
A. Cause of death includes ICD9 codes 430-439 or ICD10 codes I600-I698
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B. Primary care record review.
C. HES: diagnostic ICD9 codes 430-439 or ICD10 codes: I600-I698.
D. Participant reported physician diagnosed stroke (duration of symptoms 
>24 h).
Participants with CVD at baseline were excluded.
We performed sensitivity analyses using a stricter definition of CHD which excluded 
participant reported events and unconfirmed angina.
All participants gave written informed consent. Approval for the study at baseline was 
obtained from Ealing, Hounslow and Spelthorne, and University College London research 
ethics committees, and at follow-up from St Mary’s Hospital Research Ethics Committee 
(ref. 07/H0712/109).
Statistical analyses
Ten year risks of CVD events were calculated using the Kaplan-Meier method. QRISK2 
scores at baseline were calculated applying the published algorithm (http://
svn.clinrisk.co.uk/qrisk2 XML source: Q68_qrisk2_2012_1_1.xml, STATA dta time stamp: 
2 January 2012, 23:10). The Framingham risk score was calculated using the published 
algorithm3 with South Asian ethnicity adjustment.19 For primary analyses we assumed null 
values for baseline data which were not available for the majority of participants (see online 
supplemental table S1). We examined ethnicity specific calibration of each score by plotting 
observed against predicted risk by tenths of predicted risk and by calculation of the Brier 
score (lower values indicate greater accuracy) and the ratio of predicted to observed risk.
We assessed discrimination (differentiation of scores between participants who did and did 
not experience an event) by calculating the area under the receiver operating characteristics 
curve (AUROC) statistic for the end point of combined fatal and non-fatal CVD events. In 
addition, we calculated the D statistic (a measure of separation based on the ability of the 
prognostic index to discriminate between participants’ risks of an event) and R2 statistic,23 
24 which estimates the proportion of explained variance (higher values indicate better 
discrimination).
We compared high (≥20%) and low risk groups for each risk score and examined 
proportions of participants who would be reclassified to a different category using the 
alternative risk score and the proportion of observed events identified by high risk 
classification.
Sensitivity analyses—We repeated the above analyses recalculating QRISK2 and 
Framingham scores19 (a) using parental history data, (b) using the stricter definition of 
CHD, and (c) using the subset of African Caribbeans and Europeans with baseline ECG data 
for definition of LVH.
All analyses were conducted in STATA V.12.
Tillin et al. Page 4
Heart. Author manuscript; available in PMC 2016 May 17.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Results
Of the original 4539 participants without CVD at baseline, 4228 were traceable at follow-up. 
Follow-up data were available for 3821 (90%). Of measured risk factors, 89 (2.3%) 
participants had missing values for lipids, a Townsend score could not be assigned to 55 
addresses (1.4%), and a further three had missing data for smoking or body mass index 
(BMI). Data on chronic kidney disease were not collected at baseline; however, only three 
participants had proteinuria and <5% had microalbuminuria (table 1). Only 1% of men and 
no women had atrial fibrillation at baseline (subset of 1163 European and African Caribbean 
participants). In the same subset, 13% had tall R waves on ECG, suggesting LVH. No 
participants were receiving statins at baseline. Assuming null values for family history, 
rheumatoid arthritis, atrial fibrillation, chronic kidney disease and LVH, we were able to 
calculate both QRISK2 and Framingham scores in 3674 (87% of those traced) (see online 
supplemental figure S1). Our study participants had higher Townsend scores (more 
deprived) than the general population of England and Wales (table 1). Baseline 
characteristics of those lost to follow-up or with missing baseline data were similar to those 
included in these analyses (see online supplemental Table S2).
Three-quarters of the participants were men, 49% were European, 36% were South Asian, 
and 15% were African Caribbean, reflecting the ethnicity–sex composition of the baseline 
group. As expected, diabetes was more frequent in South Asians and African Caribbeans. 
South Asians had less favourable lipid profiles, and African Caribbeans more favourable 
lipid profiles, than Europeans. Smoking was most frequent in Europeans (table 1).
During follow-up, 387 CVD events occurred in men (14%) and 78 in women (8%); 82% of 
these were CHD events. Rates were highest in South Asians and lowest in African 
Caribbeans (figure 1).
Calibration
Both scores under-predicted risk in European and South Asian women (ratio of predicted to 
observed risk: European women: QRISK2 0.73, Framingham 0.73; South Asian women: 
QRISK2 0.52, Framingham 0.43) (table 2). Both scores more closely approximated 
observed risk in European and South Asian men. In African Caribbean men, Framingham 
over-predicted, while QRISK2 showed a closer relationship with observed risk. In African 
Caribbean women both scores over-predicted; however, numbers of events were particularly 
small in African Caribbeans and Brier scores for both scores suggested better calibration in 
African Caribbeans (table 2, figures 1 and 2). In the subset of survivors with parental history 
data, both scores still notably under-predicted observed risk in South Asian women.
In the ECG subset, addition of LVH to the Framingham score increased over-prediction of 
risk in African Caribbeans and in European men.
Discrimination
There was little difference in the discriminative performance of the two scores. The AUROC 
for men was 0.72 for both, and the D and R2 statistics were modest at 1.20% and 25.7% for 
QRISK2 and 1.22% and 26.2% for Framingham. In women, the D and R2 statistics were 
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1.31% and 29.1% for QRISK2 and 1.30% and 28.7% for Framingham. Discrimination was 
poorest for African Caribbeans for both scores (table 2). Repeat of discrimination analyses 
for the subset of survivors with family history data gave marginally better discrimination 
with overall AUROC of 0.74 for both scores. The D and R2 statistics in this subset overall 
were 1.30% and 28.7% (95% CI 21.0% to 36.0%) for QRISK2 and 1.34% and 30.0% (95% 
CI 22.3% to 37.3%) for Framingham. Addition of parental history data improved 
discrimination for both scores in African Caribbeans (AUROC: 0.75 for both scores). 
Addition of ECG identified LVH did not improve discrimination for Framingham.
Classification
One third of men (925) were classified as high risk (≥20%) by Framingham compared with 
617 (23%) men classified high risk by QRISK2. In women, 80 (9%) (Framingham) and 66 
(7%) (QRISK2) were classified as high risk. In 683 men and women identified by QRISK2 
as high risk, 193 (28%) had CVD events (accounting for 42% of total events). In 1025 men 
and women identified by Framingham as high risk, 251 (24%) had CVD events (accounting 
for 54% of total events). Reclassification from high risk Framingham to low risk QRISK2 
would have occurred in 354 (38%) men and 29 (36%) women. Reclassification from high 
risk QRISK2 to low risk Framingham would have occurred in 46 (2.5%) men and 15 (1.7%) 
women (see online supplemental table S3). There were pronounced ethnic differences in 
classification. Of 107 African Caribbeans classified as high risk by Framingham, only nine 
experienced events (24% of total events), while of 38 African Caribbeans classified as high 
risk by QRISK2, only four experienced events (10% of total events). In 30 South Asian 
women who experienced events, QRISK2 identified 10 (33%) and Framingham identified 13 
(43%) as high risk.
A similar picture was observed for classification in the subset with parental history data.
Further sensitivity analyses using a stricter definition of CHD in defining the CVD outcome 
produced similar findings for calibration, discrimination, and classification.
Discussion
In this British population based cohort, QRISK2 underpredicted risk in South Asian and 
European men and women, while Framingham under-predicted risk in South Asian women 
and over-predicted in African Caribbeans. Both scores discriminated modestly between 
Europeans and South Asians who did and did not experience events, but performed less well 
in African Caribbeans. Using the conventional 20% threshold to identify people at high risk 
of CVD events, Framingham classified 50% more people as high risk than QRISK2. 
However, these high risk categories predicted only 54% (Framingham) and 42% (QRISK2) 
of all CVD events during 10 years of follow-up. Classification was particularly poor in 
African Caribbeans. Using these scores to define high risk African Caribbeans would predict 
less than one quarter of events. For South Asian women, QRISK2 high risk classification 
was also poor and would have predicted only one third of events. Inclusion of family history 
in risk score calculation improved discrimination (but not calibration) properties of both 
scores in African Caribbeans.
Tillin et al. Page 6
Heart. Author manuscript; available in PMC 2016 May 17.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Given that the UK has large minority populations of South Asian and African Caribbean 
origins, with notably different rates of CVD compared with the European population, it is 
increasingly important that prevention measures are appropriately targeted.
We chose to consider the performance of QRISK2, which includes adjustments for ethnicity 
and deprivation and has been developed and tested using large UK primary care databases.4 
18 As a comparator, the Framingham 1991 score3 (incorporating NICE recommended 
adjustment for South Asian men), is familiar to most physicians and, until recently, was the 
risk predictor of choice according to UK national guidelines.19 We had expected QRISK2 to 
outperform the Framingham score in our UK tri-ethnic population, given that the 
Framingham score’s appropriateness to non-European populations with varied 
socioeconomic status has been questioned.5 16 17 However, our results do not suggest clear 
superiority of QRISK2 in men and women in any of the three ethnic groups. 
Underestimation of risk in South Asians, particularly in women, by both scores is of 
concern. The NICE ethnicity adjustment (Framingham score x 1.4) for South Asians has 
been recommended only for men,19 but our findings suggest that a risk multiplier for the 
Framingham score might also be considered for South Asian women and that further 
validation of QRISK2 is needed for this group. It is of note that the current Joint British 
Societies 2 guidelines do not advocate a South Asian multiplier, as it was considered that 
excess CHD risk in South Asians was explained by excess diabetes.1
For clinicians, classification to high risk categories is important in guiding implementation 
of preventive or therapeutic measures. The overall poor performance of the conventional cut-
point of 20% in both risk scores in predicting events is worrying, as are the pronounced 
differences between the two risk scores in classification to high risk groups, particularly with 
regard to African Caribbeans and South Asian women.
We are not aware of other validation studies of QRISK2 in datasets beyond the 
QRESEARCH and THIN primary care datasets.4 18 As is frequently observed, independent 
validation in different datasets may produce results less favourable than those of the original 
authors.25 This was the case for QRISK2 in our study which demonstrated poorer 
discrimination than has been reported in recent studies using primary care datasets.4 18 Our 
own dataset, although small, contained few missing data, whereas the very large derivation 
and validation datasets had complete data for lipids, blood pressure, BMI, and smoking for 
only 18.4% and 19.6% of women and 16% and 19% of men, and used multiple imputation 
methods to overcome this.8 18 Median follow-up was 6 years in the validation study, 
compared with our 10 year follow-up. These factors may contribute to the differences in 
performance of QRISK2 in our study compared with the validation studies. Surprisingly, the 
Framingham score, which predicted greater levels of risk in African Caribbeans, otherwise 
showed similar calibration and discrimination to QRISK2. However, our city dwelling study 
population was more deprived in terms of Townsend scores than the general population of 
England and Wales and, by design, included a large proportion of South Asians, who are 
known to be at high risk of CVD. Since the Framingham score does not include any 
socioeconomic adjustments, and has been reported to overpredict risk in comparison with 
QRISK2, it may serendipitously perform better in Europeans and South Asian men in this 
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cohort, given previous reports of over-prediction of risk in more affluent populations and 
under-prediction in high risk groups.16 17
A recent UK study compared QRISK2 and Framingham scores in association with national 
prevalence data in a UK black population and found, like us, that Framingham overestimated 
risk in black African Caribbeans, while QRISK2 performed better.26
Strengths and limitations
To our knowledge this is the largest British multi-ethnic cohort with lengthy follow-up, 
extensive risk factors measured in mid-life, and only modest attrition for CVD outcomes. 
We did not have complete baseline data regarding LVH or atrial fibrillation, nor data on 
rheumatoid arthritis or chronic kidney disease. However, our data suggest that it is likely that 
only a few people in any ethnic group would have had chronic kidney disease at baseline and 
that <1% had atrial fibrillation. This is in keeping with data from derivation and validation 
studies for QRISK and QRISK2,4 18 which showed that <1% had rheumatoid arthritis, and 
chronic kidney disease was present in <0.17%; hence, absence of these data is unlikely to 
affect our findings. Numbers of participants and CVD events are very small in women and in 
African Caribbean men and we urge caution in interpreting findings in these groups. Our 
main analyses assume null values for family history; however, findings in the subset of 
survivors who had parental history data collected at follow-up were similar to those 
observed in the main dataset. We also acknowledge that censoring due to non-CVD related 
deaths (n=86) may affect our findings. Our study baseline measurements were made over 20 
years ago and the population characteristics for each ethnic group may have changed. We 
compared findings from the Health Survey for England’s (HSE) ethnic minority study in 
2004, where, for example, the prevalence of diabetes in black Caribbean men was 5.3% in 
35- to 54-year-olds and 24.8% in those aged 55+, which compares reasonably with 
prevalence of 17% in our group (mean age 53.5±5.8 years). For South Asian men, the 
corresponding HSE prevalences were 8.1% and 24.3% compared with 19% in our study 
group (mean age 50.8±6.9 years).27 It is also likely that our findings in first generation 
migrants may not be generalisable to future generations in each ethnic minority group.
Conclusion
Over 10 years of follow-up in a UK population based cohort, QRISK2 and Framingham 
discriminated for CVD outcomes equivalently and modestly in European men and women 
and in South Asian men. Framingham over-predicted CVD events in African Caribbeans and 
both scores under-predicted in South Asian women. Classification to high risk groups 
differed notably between the two scores; neither high risk group performed well in 
predicting actual CVD events. Further validation of QRISK2 in other multi-ethnic datasets 
may be required. Particular attention should focus on identifying high risk African 
Caribbeans and South Asian women.
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Refer to Web version on PubMed Central for supplementary material.
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Key messages
What is already known about this subject
► Cardiovascular risk prediction is a cornerstone of preventive strategies.
► Until recently, UK national guidelines recommended the use of the 
Framingham score with an ethnicity related multiplier of 1.4 for South 
Asian men. More recently the QRISK2 risk score has been developed from 
UK primary care data and incorporates adjustments for ethnicity and 
socioeconomic position. QRISK2 has undergone internal and external 
validation in two general practice datasets, but its performance in ethnic 
minorities has not been reported separately.
How might this impact on clinical practice
► South Asians are at greatly elevated risk of both CHD and stroke, while in 
the UK African Caribbeans are at higher risk of stroke but lower risk of 
CHD compared with white Europeans. It is important that risk prediction 
scores are valid in all ethnic groups.
What does this study add
► Both Framingham and QRISK2 scores performed inconsistently across 
ethnic groups, particularly with regard to identifying high risk African 
Caribbeans and South Asian women in this British community based 
cohort. Further independent validation is needed in other multi-ethnic 
datasets and better methods of identifying high risk African Caribbeans and 
South Asian women are required.
Tillin et al. Page 12
Heart. Author manuscript; available in PMC 2016 May 17.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1. 
Observed and predicted risk over 10 years of follow-up.
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Figure 2. 
Plots of 10 year observed risk versus predicted risk of cardiovascular disease (CVD) (by 
tenths of predicted risk) for QRISK2 and Framingham (with South Asian male ethnicity 
adjustment) risk scores: (i) Men; (ii) Women.
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Table 1
Baseline characteristics (means±SD, geometric means (95% CI) or n (%))
European South Asian African Caribbean
Men
N 1359 1076 307
Age 52.8±7.1 50.8±6.9 53.5±5.8
SBP, mm Hg 123±17 125±17 128±17
Total cholesterol, mmol/L 6.0 (5.9 to 6.0) 5.8 (5.8 to 5.9) 5.5 (5.4 to 5.6)
HDL cholesterol, mmol/L 1.3 (1.2 to 1.3) 1.2 (1.1 to 1.2) 1.4 (1.3 to 1.4)
Cholesterol: HDL ratio 4.7 (4.7 to 4.8) 5.0 (5.0 to 5.1) 3.9 (3.8 to 4.1)
BMI, kg/m2 26.2±3.9 25.9±3.3 26.4±3.4
Smoking
     Never 368 (27%) 811 (75%) 170 (55%)
     Ex 537 (40%) 101 (9%) 58 (19%)
     <10/day current 81 (6%) 53 (5%) 26 (8%)
     10–19/day current 87 (6%) 65 (6%) 27 (9%)
     20+/day current 3286 (21%) 46 (4%) 26 (8%)
Diabetes 81 (6%) 209 (19%) 53 (17%)
Treated hypertension 99 (7%) 136 (13%) 57 (19%)
Atrial fibrillation 2/210 (1%) – 1/170 (0.6%)
Rheumatoid arthritis n/a n/a n/a
Chronic kidney disease n/a n/a n/a
Proteinuria (AER* ≥300 mg/day) 0/813 1/599 (0.02%) 0/205
Microalbuminuria (AER* ≥30 and <300 mg/day) 27/813 (3.3%) 15/599 (2.5%) 10/205 (4.9%)
LSOA based Townsend score (Deprivation index (quintiles for England and Wales))
     1 (most affluent) 65 (5%) 2 (0.2%) 0
     2 44 (3%) 2 (0.2%) 2 (0.7%)
     3 105 (8%) 24 (2%) 4 (1%)
     4 620 (46%) 289 (27%) 75 (24%)
     5 (least affluent) 525 (39%) 759 (71%) 226 (74%)
     Townsend score 2.5 (2.3 to 2.6) 3.5 (3.4 to 3.7) 4.3 (4.0 to 4.6)
Family history of CHD N=688 N=554 N=152
Parents diagnosed <60 years 66 (9.6%) 33 (6.0%) 3 (2.0%)
Women
N 444 241 247
Age 53.0±6.8 50.3±6.5 52.6±6.0
SBP, mm Hg 119±16 124±20 131±17
Total cholesterol, mmol/L 6.0 (5.9 to 6.2) 5.7 (5.6 to 5.8) 5.5 (5.4 to 5.7)
HDL cholesterol, mmol/L 1.6 (1.6 to 1.7) 1.4 (1.3 to 1.4) 1.6 (1.6 to 1.7)
Cholesterol: HDL ratio 3.7 (3.6 to 3.8) 4.2 (4.0 to 4.3) 3.4 (3.3 to 3.5)
BMI, kg/m2 26.0±4.7 27.5±4.6 29.3±4.8
Smoking
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European South Asian African Caribbean
     Never 212 (48%) 236 (98%) 206 (83%)
     Ex 100 (23%) 1 19 (8%)
     <10/day current 23 (5%) 3 (1%) 7 (3%)
     10–19/day current 51 (11%) 0 10 (4%)
     20+/day current 58 (13%) 1 5 (2%)
Diabetes 17 (4%) 38 (16%) 53 (21%)
Treated hypertension 46 (10%) 30 (12%) 69 (28%)
LSOA based Townsend score (Deprivation index (quintiles for England and Wales))
     1–2 (most affluent) 0 0 0
     3 28 (6%) 1 3 (1%)
     4 219 (49%) 101 (42%) 66 (26%)
     5 (least affluent) 203 (45%) 143 (58%) 187 (73%)
     Townsend score 3.3 (3.0 to 3.5) 3.3 (3.1 to 3.5) 4.9 (4.5 to 5.3)
Atrial fibrillation 0/249 – 0/238
Rheumatoid arthritis n/a n/a n/a
Chronic kidney disease n/a n/a n/a
Proteinuria (AER* ≥300 mg/day) 0/350 1/169 (0.06%) 0/189
Microalbuminuria (AER* ≥30 and <300 mg/day) 4/350 (1.1%) 4/169 (2.4%) 9/189 (4.8%)
Family history of CHD N=214 N=118 N=128
Parents diagnosed <60 years 24 (11.2%) 14 (11.9%) 6 (4.7%)
*AER=albumin excretion rate from timed overnight urine collections, not available in all participants.
BMI, body mass index; CHD, coronary heart disease; HDL, high density lipoprotein; LSOA, lower layer super output area; SBP, systolic blood 
pressure.
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Table 2
Discrimination and ratio of predicted to observed risk: QRISK2 and Framingham risk score by sex and 
ethnicity (95% CIs)
QRISK2 score Framingham CVD score
Men
Europeans, n=1359
   AUROC 0.70 (0.66 to 0.74) 0.71 (0.67 to 0.75)
   D statistic 1.06 (0.82 to 1.30) 1.13 (0.89 to 1.36)
   R2 statistic % 21.1 (13.9 to 28.6) 23.3 (15.9 to 30.8)
   Brier score 0.11 (0.10 to 0.13) 0.11 (0.10 to 0.12)
   Predicted: observed 0.78 (0.72 to 0.85) 0.99 (0.96 to 1.00)
South Asians, n=1076
   AUROC 0.73 (0.69 to 0.77) 0.73 (0.69 to 0.77)
   D statistic 1.22 (0.99 to 1.45) 1.23 (1.00 to 1.47)
   R2 statistic % 26.3 (19.0 to 33.5) 26.6 (19.2 to 33.9)
   Brier score 0.14 (0.12 to 0.15) 0.14 (0.12 to 0.15)
   Predicted: observed 0.71 (0.64 to 0.78) 0.93 (0.88 to 0.96)
African Caribbeans, n=307
   AUROC 0.67 (0.57 to 0.77) 0.63 (0.53 to 0.73)
   D statistic 0.96 (0.32 to 1.59) 0.80 (0.16 to 1.43)
   R2 statistic %    17.9 (2.4 to 37.6)       13.2 (0.7 to 32.8)
   Brier score 0.063 (0.040 to 0.085) 0.071 (0.052 to 0.091)
   Predicted: observed 0.95 (0.80 to 1.00) 1.52 (1.24 to 2.06)
All, n=2742
   AUROC 0.72 (0.69 to 0.74) 0.72 (0.69 to 0.75)
   D statistic 1.20 (1.04 to 1.36) 1.22 (1.06 to 1.38)
   R2 statistic % 25.7 (20.6 to 30.8) 26.2 (21.1 to 31.3)
   Brier score 0.12 (0.11 to 0.13) 0.12 (0.11 to 0.13)
   Predicted: observed 0.75 (0.71 to 0.80) 0.99 (0.97 to 1.00)
Women
Europeans, n=444
   AUROC 0.75 (0.67 to 0.82) 0.73 (0.65 to 0.80)
   D statistic 1.33 (0.79 to 1.87) 1.29 (0.75 to 1.83)
   R2 statistic % 29.7 (12.9 to 45.5) 28.5 (11.8 to 44.6)
   Brier score 0.073 (0.046 to 0.10) 0.074 (0.053 to 0.095)
   Predicted: observed 0.73 (0.57 to 0.88) 0.74 (0.57 to 0.88)
South Asians, n=241
   AUROC 0.75 (0.66 to 0.84) 0.77 (0.69 to 0.86)
   D statistic 1.55 (0.91 to 2.19) 1.59 (0.96 to 2.21)
   R2 statistic % 36.4 (16.6 to 53.3) 37.6 (18.1 to 53.9)
   Brier score    0.10 (0.063 to 0.14)        0.10 (0.073 to 0.13)
   Predicted: observed 0.52 (0.34 to 0.72) 0.43 (0.25 to 0.63)
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QRISK2 score Framingham CVD score
African Caribbeans, n=247
   AUROC 0.65 (0.54 to 0.76) 0.62 (0.48 to 0.75)
   D statistic    0.74 (0 to 1.63)       0.68 (0 to 1.58)
   R2 statistic %    11.6 (0.1 to 38.9)       10.0 (0.04 to 37.2)
   Brier score 0.066 (0.036 to 0.095) 0.066 (0.036 to 0.096)
   Predicted: observed 1.22 (1.04 to 1.84) 1.24 (1.07 to 2.00)
All, n=932
   AUROC 0.73 (0.68 to 0.78) 0.72 (0.67 to 0.78)
   D statistic 1.31 (0.94 to 1.68) 1.30 (0.93 to 1.67)
   R2 statistic % 29.1 (17.5 to 40.2) 28.7 (17.1 to 39.9)
   Brier score 0.078 (0.060 to 0.096) 0.079 (0.061 to 0.096)
   Predicted: observed    0.74 (0.63 to 84)        0.70 (0.59 to 0.80)
AUROC, area under the receiver operating characteristics curve; CVD, cardiovascular disease.
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